glp-1 drugs Agonists - What is it? The GLP-1 Revolution: From Diabetes

At baseline, the mean Hba1c level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg

The dual action provides enhanced benefits in managing both blood sugar and weight loss , offering a more comprehensive approach for individuals struggling with obesity or overweight conditions, especially those with associated health issues

Moreover, our study provides a more in-depth exploration of the temporal aspect, revealing how this risk evolves and intensifies with prolonged exposure

Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: a comparative study between mice and non-human primates

The trial involved 3,533 participants (1,767 receiving OZEMPIC and 1,766 receiving placebo) across 28 countries at around 400 clinical sites

A newer study, published in [29] , showed that 90% of patients using GLP-1RAs had slower gastrointestinal movement when tested with wireless motility capsules